Boehringer Ingelheim BioXcellenceâ„¢ offers reliable world-class biopharmaceuticals contract manufacturing to the pharmaceutical and biotechnology industry.

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Canada-UK Partnership Integrates Bioreactor Technologies

In a recent move, an international initiative is going...

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

AstraZeneca announces $50 billion of investment in the United...

We offer a complete range of services, from cell line and strain development through process development and large-scale manufacturing to fill and finish. Our extensive portfolio of capabilities and technologies includes the production of antibodies, recombinant proteins, non-antibody scaffolds, Fab fragments as well as pDNA from either mammalian cell culture or microbial fermentation systems.

Over the past 35 years we have repeatedly converted promising product ideas into commercial reality on a global scale.

  • We are your alternative to risky capital investments for moving into production capacity.
  • We help you flexibly manage demand uncertainties.
  • We offer manufacturing excellence in a cost-effective way.
  • We give you the freedom to focus on your own strategic priorities.

 

Latest stories

Related stories

Canada-UK Partnership Integrates Bioreactor Technologies

In a recent move, an international initiative is going...

Law to Decentralize Personalized Drug Manufacturing in UK

A legislation to decentralize personalized drug manufacturing in UK...

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

AstraZeneca announces $50 billion of investment in the United...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back